Johnson & Johnson (JNJ) FCF Payout Ratio Growth (1y) (2010 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-94.03% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
141.61% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-58.56% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-58.88% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-29.55% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
-29.45% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-18.46% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
128.23% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 29, 2026 |
141.61% |
| Dec 28, 2025 |
2.99% |
| Sep 28, 2025 |
-8.80% |
| Jun 29, 2025 |
72.19% |
| Mar 30, 2025 |
-12.13% |
| Dec 29, 2024 |
21.66% |
| Sep 29, 2024 |
-2.63% |
| Jun 30, 2024 |
-36.61% |
| Mar 31, 2024 |
-18.08% |
| Dec 31, 2023 |
-76.86% |
| Apr 2, 2023 |
48.69% |
| Apr 3, 2022 |
5.59% |
| Oct 3, 2021 |
6.40% |
| Jul 4, 2021 |
-34.94% |
| Apr 4, 2021 |
-14.60% |
| Jan 3, 2021 |
-22.18% |
| Sep 27, 2020 |
-5.62% |
| Jun 28, 2020 |
93.14% |
| Mar 29, 2020 |
10.44% |
| Dec 29, 2019 |
-0.59% |
| Sep 29, 2019 |
-16.80% |
| Jun 30, 2019 |
6.33% |
| Mar 31, 2019 |
8.59% |
| Dec 30, 2018 |
5.55% |
| Sep 30, 2018 |
7.59% |
| Jul 1, 2018 |
4.28% |
| Apr 1, 2018 |
-17.17% |
| Dec 31, 2017 |
-41.96% |
| Apr 2, 2017 |
-30.88% |
| Apr 3, 2016 |
59.76% |
| Sep 27, 2015 |
-23.02% |
| Jun 28, 2015 |
4.77% |
| Mar 29, 2015 |
47.37% |
| Dec 28, 2014 |
-8.40% |
| Sep 28, 2014 |
39.07% |
| Jun 29, 2014 |
-2.78% |
| Mar 30, 2014 |
-43.80% |
| Dec 29, 2013 |
-9.58% |
| Sep 29, 2013 |
-7.45% |
| Jun 30, 2013 |
-5.64% |
| Mar 31, 2013 |
47.82% |
| Dec 30, 2012 |
-88.85% |
| Apr 1, 2012 |
-13.30% |
| Apr 3, 2011 |
92.03% |
| Oct 3, 2010 |
11.53% |
| Jul 4, 2010 |
-7.59% |
| Apr 4, 2010 |
-22.97% |